Itraconazole

Chemical formula: C₃₅H₃₈Cl₂N₈O₄  Molecular mass: 705.633 g/mol  PubChem compound: 55283

Therapeutic indications

Itraconazole is indicated for:

Oesophageal candidosis in HIV-positive or immunocompromised

Population group: only adults (18 years old or older)

For the treatment of oral and/or oesophageal candidosis in HIV-positive or other immunocompromised patients.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Prophylaxis of deep fungal infections

Population group: only adults (18 years old or older)

As prophylaxis of deep fungal infections anticipated to be susceptible to itraconazole, when standard therapy is considered inappropriate, in patients with haematological malignancy or undergoing bone marrow transplant, and who are expected to become neutropenic (i.e. <500 cells/µl). At present there are insufficient clinical efficacy data in the prevention of aspergillosis.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Fungal infections

Population group: only adults (18 - 65 years old)

Itraconazole is indicated in the following systemic fungal conditions when first-line systemic anti-fungal therapy is inappropriate or has proved ineffective. (This may be due to underlying pathology, insensitivity of the pathogen or drug toxicity).

Treatment of aspergillosis, candidosis and cryptococcosis (including cryptococcal meningitis): in immunocompromised patients with cryptococcosis and in all patients with cryptococcosis of the central nervous system.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Itraconazole is contraindicated in the following cases:

Hypersensitivity to itraconazole

Itraconazole allergy

Pregnancy

Pregnancy

Disopyramide

Disopyramide

Dofetilide

Dofetilide

Dronedarone

Dronedarone

Quinidine

Quinidine

Dabigatran

Dabigatran

Ticagrelor

Ticagrelor

Halofantrine

Halofantrine

Mizolastine

Mizolastine

Ergot alkaloids

at least one of
Ergot alkaloids
Ergot alkaloids
Ergot alkaloids
Ergot alkaloids

Terfenadine

Terfenadine

Irinotecan

Irinotecan

Lurasidone

Lurasidone

Midazolam

Midazolam

Pimozide

Pimozide

Quetiapine

Quetiapine

Sertindole

Sertindole

Triazolam

Triazolam

Bepridil

Bepridil

Lercanidipine

Lercanidipine

Nisoldipine

Nisoldipine

Aliskiren

Aliskiren

Ivabradine

Ivabradine

Ranolazine

Ranolazine

Eplerenone

Eplerenone

Cisapride

Cisapride

Domperidone

Domperidone

Lovastatin

Lovastatin

Simvastatin

Simvastatin

Darifenacin

Darifenacin

Fesoterodine in moderate to severe renal or moderate to severe hepatic impairment

Fesoterodine and additionally at least one of



Renal failure stage 5: Kidney failure (GFR <15 mL/min/1.73 m2 or dialysis)
Hepatic failure stage III
Hepatic failure stage IV

Sildenafil, pulmonary arterial hypertension

Sildenafil and additionally Pulmonary hypertensive arterial disease

Solifenacin in moderate to severe renal or moderate to severe hepatic impairment

Solifenacin

Vardenafil

Vardenafil

Colchicine in renal or hepatic impairment

Colchicine and additionally at least one of
Renal failure
Hepatic insufficiency

CYP3A4 substrates known to prolong the QT interval

CYP3A4 substrates and additionally Drugs prolonging QT interval

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.